The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GCLLSG 2016 | Tsunami of evidence in CLL
Clemens Wendtner, MD of Klinikum Schwabing, Munich, Germany, highlights key advances in the field of chronic lymphocytic leukemia (CLL) discussed at the German CLL Study Group (GCLLSG) 2016 meeting. Dr Wendtner mentions the importance of subclones in CLL, new kinase inhibitor combinations, and immunotherapy. Using checkpoint inhibitors combined with immunostimulatory drugs may be a new avenue in CLL research. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
